Vericel Corporation (NASDAQ:VCEL) Could Improve Your Long Portfolio After Less Shorts Reported

March 14, 2018 - By Hazel Jackson

 Vericel Corporation (NASDAQ:VCEL) Could Improve Your Long Portfolio After Less Shorts Reported

The stock of Vericel Corporation (NASDAQ:VCEL) registered a decrease of 7.75% in short interest. VCEL’s total short interest was 1.01M shares in March as published by FINRA. Its down 7.75% from 1.09 million shares, reported previously. With 710,400 shares average volume, it will take short sellers 1 days to cover their VCEL’s short positions. The short interest to Vericel Corporation’s float is 3.55%.

The stock increased 2.64% or $0.3 during the last trading session, reaching $11.65. About 1.13 million shares traded or 15.95% up from the average. Vericel Corporation (NASDAQ:VCEL) has declined 10.47% since March 14, 2017 and is downtrending. It has underperformed by 27.17% the S&P500.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, makes, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company has market cap of $406.68 million. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. It currently has negative earnings. The firm also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

Vericel Corporation (NASDAQ:VCEL) Ratings Coverage

Among 4 analysts covering Vericel (NASDAQ:VCEL), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Vericel had 12 analyst reports since March 11, 2016 according to SRatingsIntel. On Tuesday, January 2 the stock rating was maintained by Piper Jaffray with “Buy”. The firm has “Buy” rating given on Wednesday, August 9 by BTIG Research. The company was downgraded on Tuesday, April 5 by Bank of America. Needham upgraded the stock to “Buy” rating in Friday, March 11 report. The stock of Vericel Corporation (NASDAQ:VCEL) has “Buy” rating given on Tuesday, November 7 by BTIG Research. The stock of Vericel Corporation (NASDAQ:VCEL) has “Buy” rating given on Monday, March 5 by BTIG Research. Piper Jaffray initiated it with “Overweight” rating and $6 target in Thursday, December 22 report. Needham maintained the shares of VCEL in report on Wednesday, November 9 with “Buy” rating. Piper Jaffray maintained it with “Buy” rating and $700 target in Wednesday, August 9 report. The firm has “Buy” rating by Piper Jaffray given on Tuesday, October 3.

More notable recent Vericel Corporation (NASDAQ:VCEL) news were published by: which released: “Vericel to Present at the 13th Annual Canaccord Genuity Musculoskeletal Conference” on February 26, 2018, also with their article: “Vericel Corp. (VCEL) Has Climbed To A New High Following Q4 Report” published on March 05, 2018, published: “Technical Perspectives on Biotech Stocks — Vericel, Viking Therapeutics …” on March 14, 2018. More interesting news about Vericel Corporation (NASDAQ:VCEL) were released by: and their article: “Vericel to Present at BioCentury’s 25th Annual Future Leaders in the Biotech …” published on March 09, 2018 as well as‘s news article titled: “Vericel to Present at the 17th Annual Needham Healthcare Conference” with publication date: March 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.